These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 27115835)
21. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. Temps C; Lietha D; Webb ER; Li XF; Dawson JC; Muir M; Macleod KG; Valero T; Munro AF; Contreras-Montoya R; Luque-Ortega JR; Fraser C; Beetham H; Schoenherr C; Lopalco M; Arends MJ; Frame MC; Qian BZ; Brunton VG; Carragher NO; Unciti-Broceta A Cancer Res; 2021 Nov; 81(21):5438-5450. PubMed ID: 34417202 [TBL] [Abstract][Full Text] [Related]
22. Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors. Dong R; Zhou X; Wang M; Li W; Zhang JY; Zheng X; Tang KX; Sun LP Bioorg Med Chem; 2021 Jan; 29():115876. PubMed ID: 33246255 [TBL] [Abstract][Full Text] [Related]
23. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Zhang X; Raghavan S; Ihnat M; Thorpe JE; Disch BC; Bastian A; Bailey-Downs LC; Dybdal-Hargreaves NF; Rohena CC; Hamel E; Mooberry SL; Gangjee A Bioorg Med Chem; 2014 Jul; 22(14):3753-72. PubMed ID: 24890652 [TBL] [Abstract][Full Text] [Related]
24. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
25. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors. Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417 [TBL] [Abstract][Full Text] [Related]
28. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. Radi M; Brullo C; Crespan E; Tintori C; Musumeci F; Biava M; Schenone S; Dreassi E; Zamperini C; Maga G; Pagano D; Angelucci A; Bologna M; Botta M Bioorg Med Chem Lett; 2011 Oct; 21(19):5928-33. PubMed ID: 21856155 [TBL] [Abstract][Full Text] [Related]
29. Novel guanidine derivatives targeting leukemia as selective Src/Abl dual inhibitors: Design, synthesis and anti-proliferative activity. Moustafa AH; AboulMagd AM; Ali AM; Khodairy A; Marzouk AA; Nafady A; T M Nemr M Bioorg Chem; 2024 Jun; 147():107410. PubMed ID: 38688197 [TBL] [Abstract][Full Text] [Related]
30. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines. Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402 [TBL] [Abstract][Full Text] [Related]
31. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones. Lamie PF Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674 [TBL] [Abstract][Full Text] [Related]
32. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma. Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826 [TBL] [Abstract][Full Text] [Related]
33. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. Zhang CH; Zheng MW; Li YP; Lin XD; Huang M; Zhong L; Li GB; Zhang RJ; Lin WT; Jiao Y; Wu XA; Yang J; Xiang R; Chen LJ; Zhao YL; Cheng W; Wei YQ; Yang SY J Med Chem; 2015 May; 58(9):3957-74. PubMed ID: 25835317 [TBL] [Abstract][Full Text] [Related]
35. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo. Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437 [TBL] [Abstract][Full Text] [Related]